Location Directory

Clinical trials in Columbus, Ohio

This page shows live ClinicalTrials.gov search results for Columbus, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

10845

Shown on this page

Current sort

Institutions in Columbus

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Ohio State University Wexner Medical Center

Live official records

Open in full search

Conditions: Polycythemia Vera
Interventions: Sapablursen, Placebo; Drug
Lead sponsor: Ono Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 13
States / cities: Orange, California • Miami, Florida • Plantation, Florida + 10 more

Conditions: Stage II Prostate Adenocarcinoma AJCC v7
Interventions: Intensity-Modulated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy; Radiation · Other
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 276
States / cities: Mobile, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 230 more

Conditions: Dravet Syndrome
Interventions: Clemizole HCl, Placebo; Drug
Lead sponsor: Epygenix; Industry
Eligibility: 2 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 31
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 27 more

Conditions: Acne Vulgaris
Interventions: Denifanstat, Placebo; Drug · Other
Lead sponsor: Sagimet Biosciences Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 23
States / cities: Bryant, Arkansas • Fremont, California • Santa Ana, California + 18 more

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Interventions: Biospecimen Collection, Cyclophosphamide, Doxorubicin, Durvalumab, Genetic Testing, Mammography, Paclitaxel, Quality-of-Life Assessment; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 3,680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 560
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 430 more

Conditions: Uveal Melanoma
Interventions: IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab; Biological · Drug
Lead sponsor: Immunocore Ltd; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 378 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 23
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 16 more

Conditions: HIV-1-infection
Interventions: VRC07-523LS, PGT121.414.LS; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 10
States / cities: Birmingham, Alabama • San Diego, California • Aurora, Colorado + 7 more

Conditions: Pneumonia
Interventions: Osteopathic Manipulative Treatment, Light-touch Treatment; Procedure
Lead sponsor: A.T. Still University of Health Sciences; Other
Eligibility: 50 Years to 100 Years
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 7
States / cities: Mount Clemens, Michigan • Kirksville, Missouri • Stratford, New Jersey + 2 more

Conditions: Graves Disease
Interventions: MER511 (IV), Placebo comparator (IV), MER511 (SC), Placebo comparator (SC), MER511 (SC) for MAD, Placebo comparator (SC) for MAD; Biological
Lead sponsor: Merida Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 11
States / cities: Torrance, California • Hollywood, Florida • Miami, Florida + 8 more

Conditions: Spinal Muscular Atrophy
Interventions: Onasemnogene Abeparvovec-brve; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 100 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 6
States / cities: Little Rock, Arkansas • Stanford, California • Boston, Massachusetts + 3 more

Conditions: Myocardial Infarction
Interventions: i-STAT hs-TnI Cartridge Testing on i-STAT 1 and i-STAT Alinity; Diagnostic Test
Lead sponsor: Abbott Point of Care; Industry
Eligibility: 18 Years and older
Enrollment: 3,697 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 28
States / cities: Chandler, Arizona • San Francisco, California • Stanford, California + 25 more

Conditions: Malignant Solid Neoplasm
Interventions: Best Practice, Financial Navigation, Interview, Survey Administration; Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: Not listed
Enrollment: 760 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 383
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 252 more

Clinical trials in Columbus, Ohio

Filter and sort this location

Institutions in Columbus

Live official records

INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)

Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection

Is Osteopathic Manipulative Treatment (OMT) Beneficial for Elderly Patients Hospitalized With Pneumonia?

NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease

ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)

Abbott i-STAT High Sensitivity Troponin I Study

Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)